Suppr超能文献

[肥胖与非肥胖受试者中β受体阻滞剂药代动力学的比较]

[Comparison of beta-blocking agents pharmacokinetics in obese and non-obese subjects].

作者信息

Cheymol G

机构信息

Service de Pharmacologie, hôpital St-Antoine, Paris.

出版信息

Bull Acad Natl Med. 1990 Oct;174(7):959-67; discussion 967-8.

PMID:1981983
Abstract

We compared in obese patients and normal subjects, the pharmacokinetics of three drugs with different solubility: d,l-sotalol markedly hydrophilic, d,l-propranolol highly lipophilic, d,l-bisoprolol moderately lipophilic. In obese subjects the pharmacokinetic data calculated for sotalol (total clearance (CL), volume of distribution (V beta), half-life of elimination (t1/2), were comparable with those measured in the controls. Data on bisoprolol showed that total V beta increased with excess of body weight, but V beta/kg of body weight was lower in obese subjects than in the controls, CL tended to increase and t1/2 was similar. As concerned propranolol, total V beta and V beta/kg were significantly lower in obese than in control subjects. Cl was decreased in obese patients and t1/2 was similar for both groups. It appears that in the obese the diffusion of liposoluble beta-blockers in the fatty excess weight remains limited. It is possible that a vasoconstrictive effect induced by beta-blockers in adipose tissues could restrict their tissular distribution.

摘要

我们比较了肥胖患者和正常受试者中三种不同溶解度药物的药代动力学

d,l-索他洛尔具有明显的亲水性,d,l-普萘洛尔具有高度的脂溶性,d,l-比索洛尔具有中等脂溶性。在肥胖受试者中,索他洛尔的药代动力学数据(总清除率(CL)、分布容积(Vβ)、消除半衰期(t1/2))与对照组中测得的数据相当。比索洛尔的数据显示,总Vβ随体重增加而增加,但肥胖受试者每千克体重的Vβ低于对照组,CL有增加趋势且t1/2相似。至于普萘洛尔,肥胖者的总Vβ和每千克体重的Vβ显著低于对照组。肥胖患者的CL降低,两组的t1/2相似。看来在肥胖者中脂溶性β受体阻滞剂在多余脂肪中的扩散仍然有限。β受体阻滞剂在脂肪组织中诱导的血管收缩作用可能会限制其组织分布。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验